Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143,290 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diseases Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

NCT02876159
View directory record Official record
Conditions
Influenza
Interventions
2016-2017 Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
20 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Iron Supplements on the Growth of Enteric Pathogens

NCT05762380
View directory record Official record
Conditions
Iron-deficiency, Iron Deficiency Anaemia Due to Dietary Causes, Iron Deficiency Anemia Treatment, Iron Deficiency Anemia
Interventions
Ferrous sulfate, Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Jul 22, 2026, 9:33 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Not applicable Interventional

The Effectiveness of Resistance Training on Glycemic Control for Patients With Type 2 Diabetes in Cardiac Rehabilitation

NCT02707380
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Cardiovascular Disease
Interventions
Resistance Training, Standard of Care
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jul 22, 2026, 9:33 PM EDT
Completed No phase listed Observational Results available

Heart at Work Study

NCT04075279
View directory record Official record
Conditions
Occupational Diseases, Cardiovascular Diseases, Cardiovascular Risk Factor, Occupational Exposure
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
35 Years to 59 Years · Male only
Enrollment
19 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 22, 2026, 9:33 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

WTC Chest CT Imaging Archive

NCT03295279
View directory record Official record
Conditions
Chronic Airway Disease, Interstitial Lung Disease, Lung Cancer
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2,122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 9:33 PM EDT
Terminated Phase 2 Interventional

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

NCT05576896
View directory record Official record
Conditions
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 9:33 PM EDT
Terminated Phase 4 Interventional Results available

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

NCT01597596
View directory record Official record
Conditions
Pompe Disease (Infantile-Onset), Glycogen Storage Disease Type II (GSD II), Glycogenosis 2, Acid Maltase Deficiency
Interventions
alglucosidase alfa
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 12 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Little Rock, Arkansas • Oakland, California • Gainsville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Phase 1 Interventional

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

NCT00513162
View directory record Official record
Conditions
Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
Interventions
Valproate, Etoposide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

NCT00000746
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1994
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

NCT01520688
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jul 22, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Animal Assisted Therapy in Pediatric Dentistry

NCT05464888
View directory record Official record
Conditions
Anxiety
Interventions
+Short AAT, +Long AAT, Active control; NO dog
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 8 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Not applicable Interventional

A Photodynamic Therapy for Treatment of Actinic Keratoses

NCT00558688
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Photodynamic therapy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Jul 22, 2026, 9:33 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

NCT03123588
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib, Anagrelide, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Jul 22, 2026, 9:33 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

NCT02934503
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Etoposide, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 9:33 PM EDT
Completed No phase listed Observational

Epicardial Fat in Coronary Artery Disease

NCT03693261
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary artery bypass grafting (CABG), Valve replacement
Procedure
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 22, 2026, 9:33 PM EDT
Not listed No phase listed Observational

Strain Echo in Acute Heart Failure

NCT02371642
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Jul 22, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

NCT05216042
View directory record Official record
Conditions
Cardiovascular Diseases, Natriuretic Peptides, Cardiometabolic Diseases, Energy Expenditure, Glucose Metabolism, Exercise, Obesity
Interventions
Study diet, Exercise capacity VO2 max determination, Exercise Challenge, Glucose Challenge
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 9:33 PM EDT
Not listed Phase 2Phase 3 Interventional

BioFreedom US IDE Feasibility Trial

NCT02131142
View directory record Official record
Conditions
Ischemic Heart Disease, Stable Angina, Unstable Angina, Silent Ischemia
Interventions
BioFreedom drug coated coronary stent
Device
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Phase 3 Interventional

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity

NCT00221442
View directory record Official record
Conditions
Binge Eating Disorder Associated With Obesity
Interventions
Zonegran, sugar pill
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 22, 2026, 9:33 PM EDT
Completed Not applicable Interventional

Attention Bias Modification Training for Social Phobia (ABMSP)

NCT06054386
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Attentional Bias Modification Training (ABMT), General Attention Control Training
Other
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Sleep Behaviors in Pregnancy

NCT04205370
View directory record Official record
Conditions
Sleep, Pregnancy Complications
Interventions
Deactivated Pregnancy Coach, Active Pregnancy Coach
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 9:33 PM EDT
No Longer Available No phase listed Expanded access

Extension Study of Drisapersen in DMD Subjects

NCT02636686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Drisapersen
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Jul 22, 2026, 9:33 PM EDT